Lumosa Therapeutics Co., Ltd. news
Lumosa`s Chief Business Officer, Mr. Christopher Aleong will be serving as one of the judges in the Innovator`s Pitch Challenge at the RESI (Redefining Early Stage Investments) Conference, on September 21~22, 2022. The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage life science and healthcare companies to gain additional exposure to conference attendees and pitch directly to a panel of judges, featuring active investors and industry experts.
The RESI confere
The Taiwan government has been promoting policies to develop the biotechnology industry since the 1980s. According to the Biotechnology and Pharmaceutical Industries Promotion Office, Ministry of Economic Affairs, Taiwan`s biotechnology/pharmaceutical industry in is valued at US$20 billion in 2020, a 7.4% growth from 2019, while the revenue of the pharmaceutical sector has reached US$3 billion, a 4.09% growth from 2019. By August 2021, there were 129 listed companies, 65 in the emerging stock
We are delighted to announce that Lumosa`s LT3001 (odatroltide) has been shortlisted for the "Clinical Advance of the Year Award" at this year`s Pharma Intelligence Scrip Awards. This Award seeks to recognize success in a clinical trial of a new drug product (biological or chemical) that is expected to lead to an advance in healthcare. Other finalists include Boehringer Ingelheim and Eli Lilly`s Jardiance, Daiichi Sankyo and AstraZeneca`s Enhertu, Intellia Therapeutics` NTLA-2001, Janss